argenx SE
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Karen Massey
- Full Time Employees
- 1,863
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Laarderhoogtweg 25 Amsterdam NH Netherlands 1101 EB
- IPO Date
- May 18, 2017
- CIK
- 0001697862
- Website
- argenx.com
- Similar Companies
- Business
- argenx SE, a commercial-stage global immunology company, develops and commercializes differentiated antibody-based therapies targeting severe autoimmune diseases using its proprietary Immunology Innovation Program and SIMPLE Antibody platform; its lead product VYVGART (efgartigimod) is an FcRn blocker approved for generalized myasthenia gravis in the United States, Europe, Japan, Israel, Canada and Mainland China, as well as for chronic inflammatory demyelinating polyneuropathy, with subcutaneous formulations including pre-filled syringes launched to enhance patient access and ongoing label expansions into broader myasthenia gravis populations such as seronegative, pediatric and ocular via studies like ADAPT-SERON, ADAPT-JR and ADAPT-OCULUS; the pipeline features advancing candidates like ARGX-213 targeting FcRn, ARGX-121 for IgA, ARGX-109 for IL-6 and ARGX-220 as a novel sweeping antibody, alongside earlier programs and out-licensed assets including LP0145 (ARGX-112) to LEO Pharma for atopic dermatitis, AGMB-101 (ARGX-114) to AgomAb Therapeutics for fibrotic diseases and ARGX-115 (ABBV-151) to AbbVie for oncology. argenx SE operates in key markets including the United States, Europe, Japan and Greater China through partnerships such as with Zai Lab; it was founded in 2008 in Ghent, Belgium by Tim van Hauwermeiren, Hans de Haard and Torsten Dreier, with headquarters in Amsterdam, Netherlands, and maintains subsidiaries like argenx BV in the Netherlands, argenx SAS in France and argenx UK Ltd. Recent developments include expansion of VYVGART into immune thrombocytopenia and multifocal motor neuropathy via registrational programs like ADVANCE and EMPASSION with topline data anticipated, autoinjector development for 2027 launch, four new pipeline nominations through the Immunology Innovation Program in 2025, sustained R&D investment supported by approximately EUR 2.6 billion in cash equivalents as of late 2024, and global commercial infrastructure growth alongside strategic collaborations leveraging technologies like Halozyme's subcutaneous delivery.
Company News
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
argenx: The Sjögren's Selloff Looks Overdone
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
argenx shares drop after trial of Vyvgart in Sjögren's disease is halted
Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Argenx discontinues Vyvgart study in Sjögren's disease, shares tumble
Argenx Shares Plunge After Autoimmune-Disease Trial Halt
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
Integrated Wealth Concepts LLC Sells 725 Shares of argenex SE $ARGX
BMY or ARGX: Which Is the Better Value Stock Right Now?
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now?
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
Here's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 Months